fenofibrate and ciprofibrate

fenofibrate has been researched along with ciprofibrate in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (10.91)	18.7374
1990's	23 (41.82)	18.2507
2000's	18 (32.73)	29.6817
2010's	7 (12.73)	24.3611
2020's	1 (1.82)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Chen, X; Cryan, E; Demarest, KT; Hlasta, DJ; Matthews, JM; Rybczynski, PJ; Strauss, K; Tang, Y; Xu, JZ; Yang, M; Zhou, L	1
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Frishman, WH; Kahn, S; Zimetbaum, P	1
Krause, BR; Newton, RS	1
Bonnefis, MT; Infante, R; Petit, D; Rey, C	1
Palmer, RH	1
Hunninghake, DB; Peters, JR	1
Beaumont, JL; Beaumont, V; Buxtorf, JC; Carcone, B; Doucet, F; Edouard, L; Jacotot, B	1
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J	1
Bardot, O; Cherkaoui Malki, M; Clemencet, MC; Latruffe, N	1
Cornu-Chagnon, MC; Dupont, H; Edgar, A	1
Schonfeld, G	1
Cherkaoui Malki, M; el Kebbaj, MH; Latruffe, N	1
Dujovne, CA; Lozada, A	1
Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C	2
Bentejac, M; Bugaut, M; Causeret, C; Clemencet, MC	1
Shepherd, J	1
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W	1
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM	1
Canepo-Anson, R; Collinson, PO; Hjelm, CJ	1
Desager, JP; Harvengt, C; Horsmans, Y; Vandenplas, C	1
Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP	1
Murphy, MJ; O'Reilly, DS; Packard, CJ	1
Autier, P; Muls, E; Van Gaal, L; Vansant, G	1
Bournot, P; Bride, J; Duclos, S; Ramirez, LC	1
Beaugrand, M; Bertrand, HJ; Castera, L; de Leusse, A; Ganne-Carrié, N; Guettier, C; Levecq, H; Plumet, Y; Trinchet, JC	1
Kockx, M; Kooistra, T; Princen, HM	1
Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B	1
Wallace, KB; Zhou, S	1
Desager, JP; Devuyst, O; Goffin, E; Jamar, F	1
Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C	1
Elisaf, M; Kakafika, A; Tsimihodimos, V	1
Bargman, JM; Lipscombe, J	1
Cwalina, L; Herman, ZS; Kalina, Z; Kowalski, J; Lebek, M; Okopien, B; Wisniewska-Wanat, M; Zielinski, M	1
Achimastos, A; Bairaktari, E; Elisaf, M; Goudevenos, J; Kakafika, A; Liamis, G; Miltiadous, G; Tsimihodimos, V	1
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V	1
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D	1
Betz, W; Devroey, D; Duquet, W; Velkeniers, B	1
Dzúrik, R; Gajdos, M	1
Romaniv, S; Vecka, M; Zák, A; Zeman, M	1
Anderson, SP; Brown, AR; Brown, HR; Cariello, NF; Colton, HM; Dahl, RR; Hoivik, DJ; Kimbrough, CL; Miller, RT; Mirabile, RC; Morgan, RJ; Mudd, PN; Oliver, WB; Qualls, CW; Santostefano, MJ; Zhao, Z	1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Berneis, K; Rizzo, M	1
Antonelli, A; Benvenga, S; Bernini, G; Corrado, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Pupilli, C	1

Reviews

7 review(s) available for fenofibrate and ciprofibrate

Article	Year
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. Journal of clinical pharmacology, 1991, Volume: 31, Issue:1 Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides	1991
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levels. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids	1987
The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis, 1994, Volume: 111, Issue:2 Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors	1994
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids	1994
Mechanism of action of fibrates. Postgraduate medical journal, 1993, Volume: 69 Suppl 1 Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL	1993
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Current medical research and opinion, 2007, Volume: 23, Issue:5 Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome	2007

Trials

8 trial(s) available for fenofibrate and ciprofibrate

Article	Year
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Effects of several lipid-lowering drugs on skin total and esterified cholesterol. Monographs on atherosclerosis, 1986, Volume: 14 Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Probucol; Random Allocation; Skin	1986
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis, 1985, Volume: 54, Issue:3 Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors	1985
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clinical cardiology, 1995, Volume: 18, Issue:11 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1995
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis, 1996, Volume: 124 Suppl Topics: Adult; Chromatography, High Pressure Liquid; Clofibric Acid; Cross-Over Studies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Fibric Acids; Half-Life; Humans; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Liver; Male; Nephelometry and Turbidimetry; Reference Values	1996
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. International journal of clinical pharmacology and therapeutics, 2001, Volume: 39, Issue:12 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thrombosis; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides	2001
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Current medical research and opinion, 2002, Volume: 18, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clofibric Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome	2002
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]. Casopis lekaru ceskych, 2003, Volume: 142, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin	2003

Other Studies

41 other study(ies) available for fenofibrate and ciprofibrate

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists. Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24 Topics: Amino Acids; Animals; Butyrates; Combinatorial Chemistry Techniques; Drug Design; Humans; Indans; Mice; Mice, Inbred Strains; Molecular Structure; PPAR alpha; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Urea	2007
Probing the fibrate binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17 Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis, 1986, Volume: 59, Issue:1 Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates	1986
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis, 1988, Volume: 74, Issue:3 Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperlipidemias; Lipids; Lipoproteins; Liver; Male; Propionates; Rats; Rats, Inbred Strains	1988
Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression. Biochemical pharmacology, 1995, Sep-28, Volume: 50, Issue:7 Topics: Acyl-CoA Oxidase; Animals; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; Microbodies; Microsomes, Liver; Mitochondria, Liver; Oxidoreductases; Proto-Oncogene Proteins; Rats; Rats, Wistar; Time Factors	1995
Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundamental and applied toxicology : official journal of the Society of Toxicology, 1995, Volume: 26, Issue:1 Topics: Animals; Cells, Cultured; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Fenofibrate; Fibric Acids; Guinea Pigs; Humans; Liver; Male; Mass Spectrometry; Microbodies; Mixed Function Oxygenases; Palmitoyl Coenzyme A; Rats; Rats, Wistar; Species Specificity; Time Factors; Tumor Cells, Cultured	1995
Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochemistry and molecular biology international, 1995, Volume: 35, Issue:1 Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Binding, Competitive; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hydroxybutyrate Dehydrogenase; Hypolipidemic Agents; In Vitro Techniques; Intracellular Membranes; Male; Microbodies; Mitochondria; Mitochondria, Liver; Phospholipids; Rats; Rats, Wistar; Tetrahymena pyriformis	1995
Hypercholesterolemia treatment in a renal transplant patient. Clinical nephrology, 1994, Volume: 41, Issue:5 Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin	1994
Creatinine rise after fibrate therapy in renal graft recipients. Lancet (London, England), 1993, Mar-27, Volume: 341, Issue:8848 Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney Transplantation; Male	1993
Effects of two peroxisome proliferators (ciprofibrate and fenofibrate) on peroxisomal membrane proteins and dihydroxyacetone-phosphate acyl-transferase activity in rat liver. Cellular and molecular biology (Noisy-le-Grand, France), 1993, Volume: 39, Issue:1 Topics: Acyltransferases; Animals; Clofibric Acid; Enzyme Induction; Fenofibrate; Fibric Acids; Glycerol-3-Phosphate O-Acyltransferase; Hydrogen-Ion Concentration; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Membrane Proteins; Microbodies; Rats; Rats, Wistar	1993
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. The Biochemical journal, 1996, Mar-15, Volume: 314 ( Pt 3) Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S	1996
Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Annals of clinical biochemistry, 1996, Volume: 33 ( Pt 2) Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Monitoring, Physiologic	1996
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications, 1996, Dec-13, Volume: 687, Issue:2 Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity	1996
Fibrates and HDL cholesterol. Annals of clinical biochemistry, 1997, Volume: 34 ( Pt 1) Topics: Apolipoprotein A-I; Cholesterol, HDL; Clofibric Acid; Dose-Response Relationship, Drug; Female; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Middle Aged; Probucol	1997
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21, Issue:2 Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss	1997
Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate. European journal of cell biology, 1997, Volume: 72, Issue:4 Topics: 3-Hydroxyacyl CoA Dehydrogenases; Animals; Cells, Cultured; Clofibric Acid; Enoyl-CoA Hydratase; Fenofibrate; Fibric Acids; Hepatoblastoma; Humans; Isomerases; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Microbodies; Microscopy, Electron; Multienzyme Complexes; Oxidoreductases; Peroxisomal Bifunctional Enzyme; Rats; Rats, Wistar; Tumor Cells, Cultured	1997
[Autoimmune hepatitis induced by fibrates]. Gastroenterologie clinique et biologique, 1998, Volume: 22, Issue:5 Topics: Aged; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Male; Middle Aged	1998
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha. Thrombosis and haemostasis, 1998, Volume: 80, Issue:6 Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin	1998
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood, 1999, May-01, Volume: 93, Issue:9 Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides	1999
The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicological sciences : an official journal of the Society of Toxicology, 1999, Volume: 48, Issue:1 Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene	1999
Implication of fibrate therapy for homocysteine. Lancet (London, England), 1999, Oct-02, Volume: 354, Issue:9185 Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Transplantation; Renal Plasma Flow, Effective	1999
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:12 Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea	2000
Fibrate treatment can increase serum creatinine levels. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:6 Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Urea	2001
Fibrate-induced increase in blood urea and creatinine. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7 Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases	2001
Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis, 2002, Volume: 165, Issue:1 Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome	2002
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's archives of pharmacology, 2003, Volume: 367, Issue:3 Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured	2003
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta cardiologica, 2003, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies	2003
Fibrates and renal function. Clinical nephrology, 2003, Volume: 60, Issue:1 Topics: Adult; Aged; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Humans; Hypolipidemic Agents; Kidney; Male; Middle Aged	2003
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 2004, Volume: 25, Issue:9 Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Area Under Curve; Catalase; Cell Division; Clofibric Acid; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Endoplasmic Reticulum, Smooth; Fenofibrate; Fibric Acids; Gene Expression Profiling; Glutathione Peroxidase; Liver; Macaca fascicularis; Male; Mitochondria; Mitotic Index; Organ Size; Oxidative Stress; Peroxisomes; Proliferating Cell Nuclear Antigen; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thioredoxin-Disulfide Reductase; Transcription Factors	2004
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3 Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2004
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Experimental cell research, 2011, Jul-01, Volume: 317, Issue:11 Topics: Antiviral Agents; Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Fibric Acids; Graves Disease; Humans; Hypolipidemic Agents; Interferon-gamma; PPAR alpha; Thyroid Gland; Tumor Necrosis Factor-alpha	2011